Skip to main content
. Author manuscript; available in PMC: 2016 May 1.
Published in final edited form as: Nanomedicine. 2015 Feb 11;11(4):959–967. doi: 10.1016/j.nano.2015.01.013

Figure 1. NP1-MNP-PEG stops and reverses age-associated bone loss in aged mice in vivo.

Figure 1

Aged female C57BL6 mice were injected IP with vehicle (PBS) or 30 mg/Kg/week NP1-MNP-PEG beginning at 20 months of age for 16 weeks. (A) Femoral BMD was monitored prospectively by DXA at monthly intervals up to 24 months of age (4 months). *P ≤ 0.05; N=10-12 mice/group. (B) Representative high resolution (6 μm) μCT reconstructions of trabecular (left) and cortical (right) bone compartments from vehicle and NP1-MNP-PEG treated mice. Scale bar (white line) = 500 μm. (C) Quantification by ELISA of C-terminal telopeptide of type I collagen (CTx), a marker of in vivo bone resorption in vehicle NP1-MNP-PEG treated mice. (D) Quantification by ELISA of serum osteocalcin a marker of in vivo bone formation. *P ≤ 0.05; t-test. N= 8-14 mice/group, ns=not significant.